Remplir Bio is developing cancer immunotherapies grounded in immunometabolism—the study of how cellular metabolism shapes immune function. Cofounded in 2022 by University of Pittsburgh immunologist Greg Delgoffe, the company is translating this research into a preclinical therapeutic platform. [1] [2]
A $7 million seed round, reported by Pitt in 2024, supports the company’s effort to turn academic discoveries into new approaches to cancer treatment. [1]